What is the best treatment for COVID‑19?

Best Treatment for COVID-19

For outpatients with mild to moderate COVID-19 at high risk of progression, nirmatrelvir-ritonavir (Paxlovid) is the preferred treatment, followed by molnupiravir as an alternative, both initiated within 5 days of symptom onset. 1

Outpatient Treatment by Risk Stratification

High-Risk Patients (Within 5 Days of Symptom Onset)

First-line: Nirmatrelvir-ritonavir 1

• Reduces all-cause mortality, COVID-19 mortality, hospital admissions, and serious adverse events 1
• Dose: 300 mg/100 mg orally every 12 hours for 5 days 2
• Superior to molnupiravir due to greater reduction in hospitalization and fewer safety concerns 2
• Critical caveat: Ritonavir causes extensive drug-drug interactions requiring careful medication review before prescribing 2
• Dose reduction to 150 mg/100 mg every 12 hours needed if eGFR 30-59 mL/min 2

Second-line: Molnupiravir 1

• Consider when nirmatrelvir-ritonavir is contraindicated or unavailable 1
• Reduces mortality, hospital admissions, and time to symptom resolution (moderate certainty) 2
• Major safety concern: Potential carcinogenesis based on preclinical mutagenic mechanism; contraindicated in children due to bone growth plate effects 2
• Dose: 800 mg orally twice daily for 5 days 2

Moderate-Risk Patients

• Nirmatrelvir-ritonavir suggested (conditional recommendation) due to important reduction in hospitalization, though smaller benefit than high-risk patients 2
• Molnupiravir recommended against in this population 2
• When nirmatrelvir-ritonavir availability is limited, prioritize high-risk patients 2

Low-Risk Patients

• Do not use nirmatrelvir-ritonavir or molnupiravir—benefits are trivial and do not justify costs or potential harms 2

Hospitalized Patients

Severe or Critical COVID-19

Immunomodulatory therapy is the cornerstone 2, 3, 4

Corticosteroids:

• Dexamethasone is standard of care for hospitalized patients requiring supplemental oxygen 3, 4

Add-on immunomodulators (with corticosteroids):

• Baricitinib (JAK inhibitor): Strong recommendation for severe/critical disease 2

  • Reduces mortality with moderate certainty evidence of no increase in serious adverse events 2
  • Dose: 4 mg orally daily for 14 days or until discharge 2
  • Can be crushed, dispersed in water, or given via nasogastric tube 2
  • Requires monitoring for leucopenia, renal/hepatic impairment 2

• IL-6 receptor blockers (tocilizumab/sarilumab): Recommended alongside baricitinib 2, 4

• Ruxolitinib or tofacitinib: Conditional recommendation against use due to low/very low certainty evidence and possible increased adverse events with tofacitinib 2

  • Consider only if baricitinib and IL-6 blockers unavailable 2

Antiviral therapy:

• Remdesivir: Only recommended antiviral for hospitalized patients 5
  • Improves survival, disease progression, time to recovery, and reduces readmission rates across disease severity spectrum 5
  • Particularly beneficial in patients with immunocompromising conditions 5

Treatments NOT Recommended

• Ivermectin: Do not use for outpatient COVID-19 1
• Sotrovimab: Do not use for outpatient COVID-19 1
• Monoclonal antibodies: Role has diminished due to viral variants with resistance 3

Critical Implementation Points

Timing is essential:

• Antivirals must be initiated within 5 days of symptom onset for outpatients 1, 2
• 99% of prescriptions in adults ≥65 years were given within 7 days of diagnosis 6
• Earlier administration yields better outcomes 5

Prescribing gaps exist:

• Only 16-23% of eligible adults ≥65 years received antivirals during 2024-2025, representing significant underprescribing 6
• Rural residents and those with comorbidities had lower odds of receiving prescriptions despite higher risk 6
• Vaccinated individuals were more likely to receive antivirals (aOR 1.73) 6

Drug interaction screening is mandatory:

• Use Liverpool COVID-19 drug interaction tool before prescribing nirmatrelvir-ritonavir 2
• Ritonavir affects metabolism for days after treatment completion 2

Variant considerations:

• Nirmatrelvir-ritonavir and molnupiravir maintain activity across variants due to targeting conserved viral proteins 2, 7